胃肠间质瘤转化研究与当前临床进展
胃肠间质瘤(GIST)多数由KIT或PDGFRA激活突变驱动,KIT原发突变多对伊马替尼敏感,但继发性激酶突变常导致耐药。舒尼替尼和瑞戈非尼分别获批用于伊马替尼耐药后的二线和三线治疗,但耐药仍会出现,部分原发突变对现有TKI耐药,存在未满足需求。多种新型选择性TKI及下游信号调控、靶向KIT/PDGFRA抗体和免疫检查点抑制剂等策略在早期临床试验中显示前景。
要点
- KIT或PDGFRA激活突变占GIST绝大多数,KIT原发突变多数对伊马替尼敏感。
- 继发性激酶突变是伊马替尼耐药最常见机制,舒尼替尼和瑞戈非尼分别为二、三线获批药物。
- 新型选择性TKI及下游信号调控、靶向抗体和免疫检查点抑制剂等策略在早期试验中显示前景。
核心结论
- GIST由KIT或PDGFRA激活突变驱动,现有TKI耐药后需新型选择性TKI及下游信号调控、靶向抗体和免疫检查点抑制剂等策略。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- KIT或PDGFRA突变占GIST病例85%以上,KIT原发突变多数对伊马替尼敏感。
- 伊马替尼耐药最常见原因为继发性激酶突变,舒尼替尼和瑞戈非尼分别获批用于二线和三线治疗。
- 部分GIST携带对现有TKI耐药的原发激活突变,存在未满足的医疗需求。
- 多种新型选择性TKI在早期临床试验中显示前景,可克服已知耐药机制。
临床怎么用
- 伊马替尼耐药后可按获批适应证选用舒尼替尼二线或瑞戈非尼三线治疗。
- 对现有TKI耐药的原发突变患者可关注新型选择性TKI的早期临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastrointestinal stromal tumor (GIST) is the most common soft tissue sarcoma of the gastrointestinal tract and, in the vast majority of cases, is characterized by activating mutations in KIT or, less commonly, PDGFRA. Mutations in these type III receptor tyrosine kinases (RTKs) account for over 85% of GIST cases, and the majority of KIT primary mutations respond to treatment with the tyrosine kinase inhibitor (TKI) imatinib. However, drug resistance develops over time, most commonly due to secondary kinase mutations. Sunitinib and regorafenib are approved for the treatment of imatinib-resistant GIST in the second and third lines, respectively. However, resistance to these agents also develops and new therapeutic options are needed. In addition, a small number of GISTs harbor primary activating mutations that are resistant to currently available TKIs, highlighting an additional unmet medical need. Several novel and selective TKIs that overcome known mechanisms of resistance in GIST have been developed and show promise in early clinical trials. Additional emerging targeted therapies in GIST include modulation of cellular signaling pathways downstream of KIT, antibodies targeting KIT and PDGFRA and immune checkpoint inhibitors. These advancements highlight the rapid evolution in the understanding of this malignancy and provide perspective on the encouraging horizon of current and forthcoming therapeutic strategies for GIST.
引用
- Hemming ML, Heinrich MC, Bauer S, et al. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol. 2018. PMID: 30101284. doi:10.1093/annonc/mdy309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。